RMi Pre-opening: Digging-in or shoveling out, sector earnings and econs

February 2, 2026 7:29am

Poison and venom to share value in the new month, February

I hate to be considered negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Pre-open Signals: passing on prediction, not “prognosis” today; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t!

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Friday’s RMi Closing Bell: Wipe-out … https://www.regmedinvestors.com/articles/14291

Monday: The pre-open Dow futures are DOWN -0.05% or (-25 points), the S&P futures are DOWN -0.37% or (-25 points) and the Nasdaq futures are DOWN -0.67% or (-172 points)

• U.S. stock futures Monday as trading begins a new month of trading, Monday 3/2
• European markets started the week in negative territory
• Asia Pacific markets fell

Economic Data: Auto sales, Jan. (16.1 million)

9:45 am                S&P flash U.S. manufacturing PMI             Jan.                                        51.9

10:00 am             ISM manufacturing          Jan.                        48.4%    47.9%   

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Friday: The Dow closed DOWN -179.09 points or -0.36%, the S&P closed DOWN -29.98 points or -0.43% while the Nasdaq closed DOWN -223.305 points or -0.94%
• Thursday: The Dow closed UP +55.96 points or +0.11%, the S&P closed DOWN -9.02 points or -0.13% while the Nasdaq closed DOWN -172.327 points or -0.72%
• Wednesday: The Dow closed UP +12.37 points or +0.03%, the S&P closed DOWN -0.56 points or -0.01% while the Nasdaq closed UP +40.349 points or +0.17%
• Tuesday: The Dow closed DOWN -409.11 points or -0.83%, the S&P closed UP +28.34 points or +0.41% while the Nasdaq closed UP +215.742 points or +0.91%
• Monday: The Dow closed UP +313.69 points or +0.64%, the S&P closed UP +34.69 points or +0.50% while the Nasdaq closed UP +100.112 points or +0.43%

• Last week: The S&P 500 closed up +0.04% and the Nasdaq -0.2%, while the Dow dropped -0.2%.
• The previous week: The S&P 500 was down -0.4%, the Dow -0.4% and the Nasdaq was down -0.1%.
• January: The S&P 500, Dow were up more than 1% and the Nasdaq had a 0.7% gain.

Q1/26 – Q1 February ,,,

• January – 2 holiday, 2 neutral, 8 negative and 9 positive closes  

Q4 – December,

• 1 holiday, 8 positive and 12 negative closes
• November, 1 holiday, 8 positive and 11 negative sessions
• October, 1 neutral, 10 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• Passing, could be wrong … prognosis looks bleak
• Many earnings this week and the beginning of sector releases
• Also awaiting the release of the January U.S. jobs report, due Friday morning; economists expect 55,000 jobs were added last month.

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

The title says it all … “Sector earnings and econs … Poison and venom to share value in the new month, February”

The major indexes ended Friday in the red — with the week little-changed — as investors digested a tech sell-off, wild trading in silver and gold, and the long-awaited news that President Trump will nominate financial markets stalwart Kevin Warsh to be the next chair of the Fed.<Yahoo Finance>

• The Nasdaq led the way down on Friday with a loss of roughly 1% after a steep tech sell-off on Thursday. The index ended the week down roughly 0.2%.

In the week ahead, investors' attention will be focused on Friday's jobs report. Economists expect the US economy added 65,000 jobs last month, with the unemployment rate set to hold at 4.4%.

• Readings on the manufacturing and services sector, as well as consumer sentiment from the University of Michigan, will also feature.

Since, the Q4 and FY25 earnings cycle is about to appear beginning 2/5 and 2 more on 2/14

• 2/5 – Arrowhead Pharmaceuticals (ARWR)
• 2/5 – IQVA Holdings (IQV)
• 2/12 - Vertex (VRTX)
• 2/13 – Moderna (MRNA)

Welcome to my world of defining the “grey’ in our universe!

• I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
• if I wanted to be liked, I wouldn’t have been an analyst/journalist.

February begins …

January – the last week:

• 1/30 – Friday closed negative with 6 incliners, 32 decliners and 2 flat
• 1/29 - Thursday closed positive with 22 incliners, 17 decliners and 1 flat
• 1/28 - Wednesday closed negative with 4 incliners, 35 decliners and 1 flat
• 1/27 - Tuesday closed positive with 21 incliners, 19 decliners and 0 flat
• 1/26 -Monday closed positive with 19 incliners, 18 decliners and 3 flats

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.